Chimerism analysis for clinicians: a review of the literature and worldwide practices

AG Blouin, M Askar - Bone marrow transplantation, 2022 - nature.com
This review highlights literature pertinent to chimerism analysis in the context of
hematopoietic cell transplantation (HCT). We also conducted a survey of testing practices of …

Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy …

LS Williams, KM Williams, N Gillis, K Bolton… - … and Cellular Therapy, 2023 - Elsevier
Allogeneic hematopoietic stem cell transplant (allo-HSCT) remains a key treatment option
for hematologic malignancies (HMs), although it carries significant risks. Up to 30% of …

New methods for the quantification of mixed chimerism in transplantation

C Picard, C Frassati, N Cherouat, S Maioli… - Frontiers in …, 2023 - frontiersin.org
Background Quantification of chimerism showing the proportion of the donor in a recipient is
essential for the follow-up of hematopoietic stem cell transplantation but can also be useful …

[HTML][HTML] Chimerism monitoring using biallelic single nucleotide or insertion/deletion polymorphisms: How many markers to screen?

M Vynck, F Nollet, L Sibbens, H Devos - Clinica Chimica Acta, 2022 - Elsevier
Background/aims Chimerism monitoring by means of high-throughput sequencing or
quantitative PCR of biallelic single nucleotide and insertion/deletion polymorphisms has …

Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation

P Kakodkar, Y Zhao, H Pan, F Wu, T Pearce… - Frontiers in …, 2023 - frontiersin.org
Allogenic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for
various hematological disorders. The success of allo-HSCT depends on the engraftment of …

Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation

S Miura, K Ueda, K Minakawa, KE Nollet, K Ikeda - Cells, 2024 - mdpi.com
Chimerism analysis after allogeneic hematopoietic stem cell transplantation serves to
confirm engraftment, indicate relapse of hematologic malignancy, and attribute graft failure …

Myeloablative dose of busulfan and fludarabine combined with in vivo T cell depletion is safe and effective conditioning for acute myeloid leukemia and …

D Avenoso, V Mehra, LB Slonim, M de Farias… - … and Cellular Therapy, 2023 - Elsevier
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative strategy for acute
myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The prediction of …

[HTML][HTML] Developing an Allogeneic Hematopoietic Progenitor Cell Transplant Service in a Resource-Limited Country: Challenges and Outcomes

UR Mahar, B Ahsan, U Ahmad, SW Bokhari - Cureus, 2023 - ncbi.nlm.nih.gov
Developing an Allogeneic Hematopoietic Progenitor Cell Transplant Service in a Resource-Limited
Country: Challenges and Outcomes - PMC Back to Top Skip to main content NIH NLM Logo …

Seventy-five years of service: an overview of the College of American Pathologists' proficiency testing program in histocompatibility and identity testing

HC Sullivan, MJ Gandhi, S Gaitonde… - Frontiers in …, 2023 - frontiersin.org
The Histocompatibility and Identity Testing Committee offers an overview of the College of
American Pathologists'(CAP) Proficiency Testing (PT) program, commemorating its …

Section E6. 1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired …

Y Akkari, LB Baughn, A Kim, E Karaca, G Raca… - Genetics in …, 2024 - Elsevier
Cytogenomic analyses of acquired clonal chromosomal abnormalities in neoplastic blood,
bone marrow, and/or lymph nodes are instrumental in the clinical management of patients …